Literature DB >> 21444835

Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Alejandro de la Sierra1, Julián Segura, José R Banegas, Manuel Gorostidi, Juan J de la Cruz, Pedro Armario, Anna Oliveras, Luis M Ruilope.   

Abstract

We aimed to estimate the prevalence of resistant hypertension through both office and ambulatory blood pressure monitoring in a large cohort of treated hypertensive patients from the Spanish Ambulatory Blood Pressure Monitoring Registry. In addition, we also compared clinical features of patients with true or white-coat-resistant hypertension. In December 2009, we identified 68 045 treated patients with complete information for this analysis. Among them, 8295 (12.2% of the database) had resistant hypertension (office blood pressure ≥140 and/or 90 mm Hg while being treated with ≥3 antihypertensive drugs, 1 of them being a diuretic). After ambulatory blood pressure monitoring, 62.5% of patients were classified as true resistant hypertensives, the remaining 37.5% having white-coat resistance. The former group was younger, more frequently men, with a longer duration of hypertension and a worse cardiovascular risk profile. The group included larger proportions of smokers, diabetics, target organ damage (including left ventricular hypertrophy, impaired renal function, and microalbuminuria), and documented cardiovascular disease. Moreover, true resistant hypertensives exhibited in a greater proportion a riser pattern (22% versus 18%; P<0.001). In conclusion, this study first reports the prevalence of resistant hypertension in a large cohort of patients in usual daily practice. Resistant hypertension is present in 12% of the treated hypertensive population, but among them more than one third have normal ambulatory blood pressure. A worse risk profile is associated with true resistant hypertension, but this association is weak, thus making it necessary to assess ambulatory blood pressure monitoring for a correct diagnosis and management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444835     DOI: 10.1161/HYPERTENSIONAHA.110.168948

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  206 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

Review 2.  Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?

Authors:  Antonios A Lazaridis; Pantelis A Sarafidis; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

3.  Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.

Authors:  Peter Hayes; Monica Casey; Liam G Glynn; Gerard J Molloy; Hannah Durand; Eoin O'Brien; Eamon Dolan; John Newell; Andrew W Murphy
Journal:  Br J Gen Pract       Date:  2018-05-08       Impact factor: 5.386

4.  [Resistant hypertension : What is it?].

Authors:  F C Luft
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

5.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

Review 6.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

Review 7.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 8.  Role of ambulatory blood pressure monitoring in resistant hypertension.

Authors:  Guido Grassi; Michele Bombelli; Gino Seravalle; Gianmaria Brambilla; Raffaella Dell'oro; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

Review 9.  How can resistant hypertension be identified and prevented?

Authors:  Anna Solini; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2013-03-05       Impact factor: 32.419

10.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.